Novartis invests $256m to expand Singapore biopharmaceutical plant for Asia's growing demand, creating 100 jobs and using digital/automation.

Novartis invests US$256 million to expand its Singapore biopharmaceutical manufacturing plant, addressing the growing demand in Asia. The expansion will generate 100 high-skilled jobs, focusing on manufacturing therapeutic antibody drugs. Digital and automation solutions will be deployed to enhance productivity, improve efficiency, and upskill the workforce. The site is expected to be operational by early 2026.

March 15, 2024
3 Articles

Further Reading